Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC

This interventional clinical study evaluates the clinical utility and feasibility of the Oncomine Precision Assay GX method for genotyping circulating tumor DNA (ctDNA) in patients with advanced non-small cell lung cancer (NSCLC). Participants with advanced NSCLC undergo peripheral blood sampling as part of the study intervention. Circulating tumor DNA is analyzed using the Oncomine Precision Assay GX platform. Molecular findings obtained from liquid biopsy are compared with available standard diagnostic results from tumor tissue or other clinically indicated molecular testing methods. The aim of the study is to evaluate the feasibility, diagnostic performance, and clinical applicability of ctDNA genotyping using the Oncomine Precision Assay GX method in a real-world clinical setting and to assess its potential role in routine molecular diagnostics of advanced NSCLC.

NCT Number	NCT07432308
Lead Sponsor	Institute of Oncology Ljubljana
Conditions	Non-Small Cell Lung Cancer
Enrollment	22 participants
Start Date	2024-02-01
Primary Completion	2024-08-31 (estimated)
Study Completion	2025-08-19 (estimated)
Updated on ClinicalTrials.gov	2026-03-06